{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:21:04Z","timestamp":1768875664438,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ahj.2013.09.003","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T12:57:56Z","timestamp":1382533076000},"page":"983-989.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease"],"prefix":"10.1016","volume":"166","author":[{"given":"Jennifer B.","family":"Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Angelyn","family":"Bethel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjoy K.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Ring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith D.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah R.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Califf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rury R.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2013.09.003_bb0005","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Interventional Trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2013.09.003_bb0010","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","article-title":"Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)","volume":"316","author":"Turner","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2013.09.003_bb0015","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2013.09.003_bb0020","unstructured":"International Diabetes Federation. IDF diabetes atlas (5th ed). 2011. http:\/\/www.idf.org\/diabetesatlas (accessed August 1, 2013)."},{"key":"10.1016\/j.ahj.2013.09.003_bb0025","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.09.003_bb0030","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2013.09.003_bb0035","first-page":"2643","article-title":"for the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in type 1 diabetes mellitus","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.09.003_bb0040","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.09.003_bb0045","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.ahj.2013.09.003_bb0050","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.09.003_bb0055","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.09.003_bb0060","unstructured":"Guidance for Industry: Diabetes Mellitus \u2013 Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. (2008) http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071627.pdf (accessed August 1, 2013)."},{"key":"10.1016\/j.ahj.2013.09.003_bb0065","series-title":"Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus","author":"European Medicines Agency","year":"2010"},{"key":"10.1016\/j.ahj.2013.09.003_bb0070","unstructured":"Januvia (sitagliptin) prescribing information. http:\/\/www.merck.com\/product\/usa\/pi_circulars\/j\/januvia\/januvia_pi.pdf (accessed August 1, 2013)."},{"key":"10.1016\/j.ahj.2013.09.003_bb0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2009.01173.x","article-title":"Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes","volume":"12","author":"Vilsb\u00f8ll","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ahj.2013.09.003_bb0170","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.2337\/db13-0822","article-title":"Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls","volume":"62","author":"Drucker","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.ahj.2013.09.003_bb0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-200932030-00002","article-title":"PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive","volume":"32","author":"Dormandy","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.ahj.2013.09.003_bb0090","unstructured":"Survival analysis: A self learning text. 2nd edition. David G. Kleinbaum and Mitchel Klein. 2005, Springer Science + Business Media, LLC. Chapter 4 pp.131-157."},{"key":"10.1016\/j.ahj.2013.09.003_bb0095","author":"International Conference on Harmonisation"},{"key":"10.1016\/j.ahj.2013.09.003_bb0100","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jama.295.10.1152","article-title":"Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement","volume":"295","author":"Piaggio","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2013.09.003_bb0105","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.numecd.2008.08.002","article-title":"Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk","volume":"18","author":"Mannucci","year":"2008","journal-title":"J Nutrition Metab Cardiovasc Dis"},{"key":"10.1016\/j.ahj.2013.09.003_bb0110","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/0091270008316885","article-title":"Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension","volume":"48","author":"Mistry","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2013.09.003_bb0115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13300-013-0024-0","article-title":"Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies","volume":"4","author":"Engel","year":"2013","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ahj.2013.09.003_bb0120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2010.05.2138","article-title":"A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes","volume":"122","author":"Frederich","year":"2010","journal-title":"Postgrad Med"},{"key":"10.1016\/j.ahj.2013.09.003_bb0125","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1463-1326.2010.01215.x","article-title":"Assessing the cardio-cerebral safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population","volume":"12","author":"Schweizer","year":"2010","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.ahj.2013.09.003_bb0130","unstructured":"White W, Gorelick P, Fleck P, et al. Cardiovascular events in patients receiving alogliptin: a pooled analysis of randomized clinical trials. ADA Abstract No. 0391-PP, 2010."},{"key":"10.1016\/j.ahj.2013.09.003_bb0135","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.numecd.2009.03.015","article-title":"Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"20","author":"Monami","year":"2010","journal-title":"J Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.ahj.2013.09.003_bb0140","unstructured":"Information available at: http:\/\/news.bms.com\/press-release\/astrazeneca-and-bristol-myers-squibb-announce-top-line-results-savor-timi-53-cardiovas (accessed August 1, 2013)."},{"key":"10.1016\/j.ahj.2013.09.003_bb0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11154-010-9130-8","article-title":"Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus","volume":"11","author":"Joffe","year":"2010","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.ahj.2013.09.003_bb0150","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/clpt.2011.257","article-title":"Shift from surrogate end point to outcome trials: implications for cardiovascular safety assessment in development programs for antidiabetic drugs","volume":"91","author":"Marcinak","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ahj.2013.09.003_bb0175","article-title":"Dipeptidyl peptidase-4 inhibitors and cardiovascular events: A protective effect?","author":"Lamanna","year":"2011"},{"key":"10.1016\/j.ahj.2013.09.003_bb0160","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1464-5491.2010.02941.x","article-title":"Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials","volume":"27","author":"DeFronzo","year":"2010","journal-title":"Diabet Med"},{"key":"10.1016\/j.ahj.2013.09.003_bb0165","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study","volume":"34","author":"Lewis","year":"2011","journal-title":"Diabetes Care"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870313006017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870313006017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:50:53Z","timestamp":1757569853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870313006017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0002870313006017"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2013.09.003","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2013.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}